New promising compounds with in vitro nanomolar activity against Trypanosoma cruzi

ACS Medicinal Chemistry Letters

Volumn 4, Issue 6, 2013, Pages 538-541

  Friggeri, Laura ^a   Scipione, Luigi ^a   Costi, Roberta ^a   Kaiser, Marcel ^b   Moraca, Francesca ^d   Zamperini, Claudio ^d   Botta, Bruno ^a   Di Santo, Roberto ^a   De Vita, Daniela ^a   Brun, Reto ^b,c   Tortorella, Silvano ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

^d UNIVERSITY OF SIENA   (Italy)

Author keywords

Aminopyridine; Antiparasitic activity; Azole; Chagas disease; CYP51; Trypanosoma cruzi

Indexed keywords

4 AMINOPYRIDINE DERIVATIVE; ANTIPARASITIC AGENT; BENZNIDAZOLE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CYTOTOXICITY; ENANTIOMER; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; TRYPANOSOMA CRUZI;

RATTUS; TRYPANOSOMA CRUZI;

EID: 84879097485     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400039r     Document Type: Article

References (23)

1. Hotez, P. J.; Molyneux, D. H.; Fenwick, A.; Kumaresan, J.; Ehrlich Sachs, S.; Sachs, J. D.; Savioli, L. Control of neglected tropical diseases. New Engl. J. Med. 2007, 357, 1018-27.
2. World Health Organization. Working to overcome the global impact of neglected tropical diseases. http://whqlibdoc.who.int/publications/2010/ 9789241564090-eng.pdf (accessed Nov 15, 2012).
3. Zeledón, R.; Rabinovich, J. E. Chagas' disease: an ecological appraisal with special emphasis on its insect vectors. Annu. Rev. Entomol. 1981, 26, 101-33.
4. Bern, C.; Montgomery, S. P.; Herwaldt, B. L.; Rassi, A., Jr.; Marin-Neto, J. A.; Dantas, R. O.; Maguire, J. H.; Acquatella, H.; Morillo, C.; Kirchhoff, L. V.; Gilman, R. H.; Reyes, P. A.; Salvatella, R.; Moore, A. C. Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA, J. Am. Med. Assoc. 2007, 298, 2171-2181.
5. Urbina, J. A. Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop. 2010, 115, 55-68.
6. ClinicalTrial.gov. Proof-of-concept study of E1224 to treat adult patients with Chagas disease. http://clinicaltrials.gov/ct2/show/NCT01489228? term=ravuconazole&rank=2 (accessed Apr 16, 2013).
7. De Souza, W.; Rodrigues, J. C. F. Sterol biosynthesis pathway as target for antitrypanosomatid drugs. Interdiscip. Perspect. Infect. Dis. 2009, 642-502.
8. Lepesheva, G. I.; Villalta, F.; Waterman, M. R. Targeting Trypanosoma cruzi sterol 14α-demethylase (CYP51). Adv. Parasit. 2011, 75, 65-87.
9. Lepesheva, G. I.; Hargrove, T. Y.; Anderson, S.; Kleshchenko, Y.; Furtak, V.; Wawrzak, Z.; Villalta, F.; Waterman, M. R. Structural insights into inhibition of sterol 14α-demethylase in the human pathogen Trypanosoma cruzi. J. Biol. Chem. 2010, 285 (33), 25582-25590.
10. Chen, C. K.; Leung, S. S. F.; Guilbert, C.; Jacobson, M. P.; McKerrow, J. H.; Podust, L. M. Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Neglect. Trop. D 2010, 4 (4), e651 DOI: 10.1371/journal.pntd. 0000651.
11. Gunatilleke, S. S.; Calvet, C. M.; Johnston, J. B.; Chen, C. K.; Erenburg, G.; Gut, J.; Engel, J. C.; Ang, K. K. H.; Mulvaney, J.; Chen, S.; Arkin, M. R.; McKerrow, J. H.; Podust, L. M. Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51. PLoS Neglect. Trop. D 2012, 6 (7), e1736 DOI: 10.1371/journal.pntd.0001736.
12. Chen, C. K.; Doyle, P. S.; Yermalitskaya, L. V.; Mackey, Z. B.; Ang, K. K. H.; McKerrow, J. H.; Podust, L. M. Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Neglect. Trop. D 2009, 3 (2), e372 DOI: 10.1371/journal.pntd.0000372.
13. Lepesheva, G. I.; Hargrove, T. Y.; Kleshchenko, Y.; Nes, W. D.; Villalta, F.; Waterman, M. R. CYP51: A major drug target in the cytochrome P450 superfamily. Lipids 2008, 43, 1117-1125.
14. De Vita, D.; Scipione, L.; Tortorella, S.; Mellini, P.; Di Rienzo, B.; Simonetti, G.; D'Auria, F. D.; Panella, S.; Cirilli, R.; Di Santo, R.; Palamara, A. Synthesis and antifungal activity of a new series of 2-(1Himidazol-1-yl)-1- phenylethanol derivatives. Eur. J. Med. Chem. 2012, 49, 334-342.
15. Orhan, I.; Şener, B.; Kaiser, M.; Brun, R.; Tasdemir, D. Inhibitory activity of marine sponge-derived natural products against parasitic protozoa. Mar. Drugs. 2010, 8, 47-58.
16. Lennon, I. C.; Ramsden, J. A. An efficient catalytic asymmetric route to 1-aryl-2-imidazol-1-yl-ethanols. Org. Process Res. Dev. 2005, 9, 110-112.
17. Maestro, version 9.2; Schrödinger, LLC: New York, 2011.
18. Macromodel, version 9.2; Schrödinger, LLC: New York, 2011.
19. Jones, G.; Willet, P.; Glen, R. C. Molecular recognition of receptor size using a genetic algorithm with a description of desolvation. J. Mol. Biol. 1995, 245, 43-53.
20. Hargrove, T. Y.; Wawrzak, Z.; Liu, J.; Nes, W. D.; Waterman, M. R.; Lepesheva, G. I. Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14α-demethylase (CYP51) from Leishmania infantum. J. Biol. Chem. 2011, 286, 26838-26848.
21. Jurima-Romet, M.; Crawford, K.; Cyr, T.; Inaba, T. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab. Dispos. 1994, 22, 849-857.
22. Wandel, C.; Lang, C. C.; Cowart, D. C.; Girard, A. F.; Bramer, S.; Flockhart, D. A.; Wood, A. J. Effect of CYP3A inhibition on vesnarinone metabolism in humans. Clin. Pharmacol. Ther. 1998, 63, 506-511.
23. Rando, R. R. Mechanism-based enzyme inactivators. Pharmacol. Rev. 1984, 36, 111-142.